As of 2025-03-20, the EV/EBITDA ratio of Kymera Therapeutics Inc (KYMR) is -8.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KYMR's latest enterprise value is 2,083.01 mil USD. KYMR's TTM EBITDA according to its financial statements is -249.34 mil USD. Dividing these 2 quantities gives us the above KYMR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 13.4x | 12.4x |
| Forward P/E multiples | 17.4x - 35.0x | 21.7x |
| Fair Price | (64.94) - (49.66) | (63.67) |
| Upside | -291.7% - -246.6% | -288.0% |
| Date | EV/EBITDA |
| 2025-03-19 | -8.49 |
| 2025-03-18 | -8.40 |
| 2025-03-17 | -8.52 |
| 2025-03-14 | -8.48 |
| 2025-03-13 | -8.24 |
| 2025-03-12 | -8.67 |
| 2025-03-11 | -8.20 |
| 2025-03-10 | -8.13 |
| 2025-03-07 | -8.10 |
| 2025-03-06 | -8.01 |
| 2025-03-05 | -7.79 |
| 2025-03-04 | -7.52 |
| 2025-03-03 | -7.39 |
| 2025-02-28 | -7.70 |
| 2025-02-27 | -7.41 |
| 2025-02-26 | -8.74 |
| 2025-02-25 | -8.57 |
| 2025-02-24 | -8.73 |
| 2025-02-21 | -9.12 |
| 2025-02-20 | -9.28 |
| 2025-02-19 | -9.34 |
| 2025-02-18 | -9.20 |
| 2025-02-14 | -9.14 |
| 2025-02-13 | -9.07 |
| 2025-02-12 | -8.69 |
| 2025-02-11 | -8.49 |
| 2025-02-10 | -8.92 |
| 2025-02-07 | -9.25 |
| 2025-02-06 | -9.70 |
| 2025-02-05 | -9.57 |
| 2025-02-04 | -9.62 |
| 2025-02-03 | -9.56 |
| 2025-01-31 | -9.84 |
| 2025-01-30 | -10.07 |
| 2025-01-29 | -9.79 |
| 2025-01-28 | -10.12 |
| 2025-01-27 | -10.27 |
| 2025-01-24 | -11.09 |
| 2025-01-23 | -11.05 |
| 2025-01-22 | -11.03 |
| 2025-01-21 | -10.91 |
| 2025-01-17 | -10.11 |
| 2025-01-16 | -10.03 |
| 2025-01-15 | -10.88 |
| 2025-01-14 | -9.98 |
| 2025-01-13 | -9.23 |
| 2025-01-10 | -9.47 |
| 2025-01-08 | -10.09 |
| 2025-01-07 | -10.19 |
| 2025-01-06 | -9.92 |